EPS for IRIDEX Corporation (IRIX) Expected At $-0.33

April 17, 2018 - By Nellie Frank

IRIDEX Corporation (NASDAQ:IRIX) LogoInvestors sentiment increased to 1.2 in Q4 2017. Its up 0.65, from 0.55 in 2017Q3. It increased, as 5 investors sold IRIDEX Corporation shares while 5 reduced holdings. 1 funds opened positions while 11 raised stakes. 5.52 million shares or 2.07% less from 5.63 million shares in 2017Q3 were reported.
Neuberger Berman Limited Liability Com owns 15,000 shares or 0% of their US portfolio. Bnp Paribas Arbitrage Sa has 0% invested in IRIDEX Corporation (NASDAQ:IRIX) for 32 shares. National Bank Of Mellon holds 0% or 15,408 shares. Manufacturers Life Company The reported 814 shares. 201,395 are owned by Dimensional Fund Lp. Tower Capital Lc (Trc) owns 11,823 shares. Wells Fargo & Communication Mn has invested 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX). Millennium Limited Company holds 58,412 shares or 0% of its portfolio. Acuta Capital Prns Limited Liability Company invested in 2.00 million shares or 2.88% of the stock. Lyon Street Ltd Liability holds 1.23% in IRIDEX Corporation (NASDAQ:IRIX) or 483,760 shares. First Light Asset Mgmt Lc has invested 0.66% in IRIDEX Corporation (NASDAQ:IRIX). Bridgeway Capital Incorporated owns 67,100 shares or 0.01% of their US portfolio. Ingalls & Snyder Ltd Liability Com invested 0.01% in IRIDEX Corporation (NASDAQ:IRIX). Deutsche Bank & Trust Ag accumulated 35,430 shares. California Pub Employees Retirement has 32,100 shares.

Since December 12, 2017, it had 1 buy, and 1 insider sale for $22,756 activity. 2,806 shares were sold by Dizon Romeo R, worth $16,444 on Tuesday, March 13.

Analysts expect IRIDEX Corporation (NASDAQ:IRIX) to report $-0.33 EPS on May, 2.They anticipate $0.17 EPS change or 106.25 % from last quarter’s $-0.16 EPS. After having $-0.44 EPS previously, IRIDEX Corporation’s analysts see -25.00 % EPS growth. The stock decreased 2.04% or $0.12 during the last trading session, reaching $5.76. About 18,357 shares traded. IRIDEX Corporation (NASDAQ:IRIX) has declined 53.54% since April 17, 2017 and is downtrending. It has underperformed by 65.09% the S&P500.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $66.97 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.